- Part 2: For the preceding part double click ID:nRSH4027Ra
after a drug's approval, which can result in increased costs, labelling challenges or loss of regulatory approval.Factors,
including advances in science and technology, evolving regulatory science, and different approaches to benefit/risk tolerance by
regulatory authorities, the general public, and other third party public interest groups influence the initial approvability of
new drugs. Existing marketed products are also subject to these same forces, and new data and meta-analyses have the potential
to drive changes in the approval status or labelling. Recent years have seen an increase in post-marketing regulatory
requirements and commitments, and an increased call for third party access to regulatory and clinical trial data packages for
independent analysis and interpretation, and broader data transparency.Unanticipated and unpredictable policy making by
governments and regulators can adversely influence regulatory decision making, often leading to severe delays in regulatory
approval. The predictability of the outcome and timing of review processes remains challenging due to evolving regulatory
science, competing regulatory priorities, unpredictable policy making and limits placed on regulatory authority resources.
Failure to obtain and enforce effective IP protection Impact
Our ability to obtain and enforce patents and other IP rights in relation to our products is an important element in protecting Limitations on the availability of patent protection or the use of compulsory licensing in certain countries in which we operate could have a material adverse effect on the pricing and sales of our products and, consequently, could materially adversely affect our revenues from those products. More information about protecting our IP, the risk of patent litigation and the early loss of IP rights is contained in the Intellectual Property section on page 60, the Effects of patent litigation in respect of IP rights risk on page 218 and the Expiry or loss of, or limitations to, IP rights and consequential pressure from generic competition risk on page 215.
our investment in R&D and creating long-term value for the business. Some countries in which we operate are still developing
their IP laws, others are limiting the applicability of their IP laws to certain pharmaceutical inventions. Certain countries
may seek to limit or deny effective IP protection for pharmaceuticals because of adverse political perspectives around the
desirability of appropriate IP protection for pharmaceuticals.
Commercialisation risks
Expiry or loss of, or limitations to, IP rights and consequential Impact
pressure from generic competition
A pharmaceutical product is protected from being copied for the limited If challenges to our IP by generic drug manufacturers succeed and generic products are launched, or generic products are launched 'at risk' on the expectation that challenges to our IP will be successful, this may materially adversely affect our revenues and financial condition. Furthermore, if limitations on the availability, scope or enforceability of patent protection are implemented in jurisdictions in which we operate, generic manufacturers in these countries may be increasingly able to introduce competing products to the market earlier than they would have been able to, had more robust patent protection or Regulatory Data Protection been available.
period of protection under patent rights and/or related IP rights such as
Regulatory Data Protection or Orphan Drug status. This period of
protection helps us recoup our overall R&D investment. Early loss of IP
rights may threaten our ability to recoup our investment in a patent
- More to follow, for following part double click ID:nRSH4027Rc